Novo Nordisk A/S NVO
| Analyst |
Entreprise |
Price during analysis |
Target price |
Potential gain |
Publication date |
| Evan Seigerman |
BMO Capital |
57.5 $ |
55 $ |
-2.50 % |
14/10/2025 |
| Jailendra Singh |
Truist Financial |
70.03 $ |
48 $ |
-22.03 % |
23/07/2025 |
| Evan Seigerman |
BMO Capital |
118.578 $ |
156 $ |
37.42 % |
17/10/2024 |
| Louise Chen |
Cantor Fitzgerald |
135.23 $ |
160 $ |
24.77 % |
11/09/2024 |
| Evan David Seigerman |
BMO Capital |
126.17 $ |
160 $ |
33.83 % |
08/08/2024 |
| Jasper Hellweg |
Argus Research |
142.88 $ |
160 $ |
17.12 % |
10/06/2024 |
| James Quigley |
Goldman Sachs |
132.68 $ |
156 $ |
23.32 % |
30/05/2024 |
| Evan David Seigerman |
BMO Capital |
125.4 $ |
163 $ |
37.60 % |
12/04/2024 |